Federal multidistrict litigation tracker

MDL 3140 Update — Depo-Provera Lawsuit

In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation. Counts are monthly JPML snapshots and can change between reports.

Lawsuit status — September 2026

Depo-Provera Lawsuit

Verified September 14, 2026

MDL: MDL-3140
Court: N.D. Fla.
Judge: Judge M. Casey Rodgers
Pending cases: 6,403; +109 since prior report
Current phase: Settlement registration; litigation continues for remaining claims
Settlement status: active — individual eligibility required
Latest development: JPML reports 6,403 pending actions on September 1, 2026, compared with 6,294 on August 3; 6,510 total historical actions are reported separately.
Next major event: September 18, 2026 — Rule 702 hearing (scheduled)

What changed this month?

●JPML reports 6,403 pending actions on September 1, 2026, compared with 6,294 on August 3; 6,510 total historical actions are reported separately. Source
●CMO 12 confirms a private settlement and cancellation of the original December Pilot trial; the September 18 Rule 702 hearing remains listed for ongoing litigation. Source
●The August 5 CMO 13 appoints BrownGreer PLC as settlement administrator to review records and determine eligibility. Source
●The August 10 CMO 14 identifies November 30, 2026 as the settlement registration deadline and sets procedures for continuing claims. Source

MDL details

Created: February 7, 2025
Pending: 6,403
Total actions filed: 6,510
Monthly change: +109

Defendants named in the tracked record

Pfizer Inc.; Pharmacia & Upjohn Co. LLC; Pharmacia LLC. Defendants dispute the allegations.

Historical case counts

Report	Pending	Total filed
September 1, 2026	6,403	6,510
August 3, 2026	6,294	6,394
July 1, 2026	5,830	—

What the litigation alleges

The tracked claims concern prescription drug injury claim, including meningioma brain tumors. These are allegations; defendants dispute liability and causation.

Stage and bellwether status

Court orders confirm a private settlement program documented in July 2026. CMO 13 appoints BrownGreer as administrator, and CMO 14 identifies November 30, 2026 as the registration deadline. CMO 12 states that the original December Pilot trial was canceled; the court calendar still lists a September 18 Rule 702 hearing for ongoing litigation. Eligibility and payments are not automatic.

Bellwether record: CMO 12 states the original Pilot schedule was vacated and the December trial canceled following the settlement announcement.

Settlement status

Court orders confirm a confidential settlement program for eligible Depo-Provera claims, with BrownGreer appointed administrator on August 5, 2026. CMO 14 identifies November 30, 2026 as the registration deadline. The public orders reviewed September 14 do not disclose an aggregate fund or individual payout grid. This is a private agreement, not a class settlement requiring a fairness hearing. Nonparticipating and ineligible claims continue under court procedures.

Individual claims: Court orders confirm a confidential settlement program for eligible Depo-Provera claims, with BrownGreer appointed administrator on August 5, 2026. CMO 14 identifies November 30, 2026 as the registration deadline. The public orders reviewed September 14 do not disclose an aggregate fund or individual payout grid. This is a private agreement, not a class settlement requiring a fairness hearing. Nonparticipating and ineligible claims continue under court procedures.